A systematic review and meta-analysis of interventions used to reduce exposure to house dust and their effect on the development and severity of asthma

Macdonald, Clare; Sternberg, Anna; Hunter, Paul R.

doi:10.1590/s1413-81232008000600026

Cited by 11 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…is key to identifying subgroups and tailoring treatment in clinical practice. In allergic asthma, avoidance of triggers may be a strategy, although the utility of avoidance for house dust mite allergy is debatable [134]. Omalizumab is a well-validated strategy for allergic asthma with high IgE, which reduces corticosteroid use and exacerbation rates [135] and improves long-term control [136].…”

Section: Subgroups With Treatment Implicationsmentioning

confidence: 99%

Clinically relevant subgroups in COPD and asthma

Turner

Tamási

Schleich³

et al. 2015

Eur Respir Rev

View full text Add to dashboard Cite

As knowledge of airways disease has grown, it has become apparent that neither chronic obstructive pulmonary disease (COPD) nor asthma is a simple, easily defined disease. In the past, treatment options for both diseases were limited; thus, there was less need to define subgroups. As treatment options have grown, so has our need to predict who will respond to new drugs. To date, identifying subgroups has been largely reported by detailed clinical characterisation or differences in pathobiology. These subgroups are commonly called "phenotypes"; however, the problem of defining what constitutes a phenotype, whether this should include comorbid diseases and how to handle changes over time has led to the term being used loosely.In this review, we describe subgroups of COPD and asthma patients whose clinical characteristics we believe have therapeutic or major prognostic implications specific to the lung, and whether these subgroups are constant over time. Finally, we will discuss whether the subgroups we describe are common to both asthma and COPD, and give some examples of how treatment might be tailored in patients where the subgroup is clear, but the label of asthma or COPD is not. @ERSpublications Summary of subgroups of airways disease that can be found in COPD and asthma, and their management

show abstract

Section: Subgroups With Treatment Implicationsmentioning

confidence: 99%

Clinically relevant subgroups in COPD and asthma

Turner

Tamási

Schleich³

et al. 2015

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…Hence, the consequential economic burden associated with asthma has also risen greatly [3,4]. To date, asthma treatments have not been sufficiently effective to allow a satisfactory level of control in all asthmatics [5]. Although a number of studies have attempted to unravel the secrets of this disease, the complete mechanism remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of miRNA-221 Suppresses the Airway Inflammation in Asthma

Qin

Juan-juan

et al. 2012

Inflammation

View full text Add to dashboard Cite

This study investigated the expression of miRNA-221 in asthmatics in order to determine whether miRNA-221 plays a role in the development of asthma. Real-time PCR was used to detect the miRNA-221 in both asthmatic and control subjects. In addition, airway inflammation was evaluated by cell counting and tissue biopsy in the OVA-induced murine asthma model. miRNA-221 was differentially expressed in asthmatics and control subjects, and miRNA-221 blockade resulted in a reduction of airway inflammation in the OVA-induced murine asthma model. We conclude that miRNA-221 participates in the pathogenesis of asthma and that inhibition of miRNA-221 suppresses airway inflammation in asthmatics.

show abstract

“…Many studies have attempted to prevent allergies and asthma by controlling HDM and other allergens in the home environment. A recent meta-analysis 38 reported a significant reduction in physician-diagnosed asthma as a result of interventions to reduce exposure to HDM (relative risk [RR]=0.74; 95% confidence interval [CI], 0.58-0.95). There was, however, no significant effect on parent-reported wheeze (RR=0.95; 95% CI, 0.78-1.15).…”

Section: Indoor Environmentmentioning

confidence: 99%

Guidelines for allergy prevention in Hong Kong

et al. 2016

Hong Kong Med J

View full text Add to dashboard Cite

A systematic review and meta-analysis of interventions used to reduce exposure to house dust and their effect on the development and severity of asthma

Abstract: Revisão sistemática e meta-análise de intervenções para reduzir a exposição à poeira doméstica e seu efeito sobre o desenvolvimento e severidade da asma

Cited by 11 publications

References 23 publications

Clinically relevant subgroups in COPD and asthma

Clinically relevant subgroups in COPD and asthma

Inhibition of miRNA-221 Suppresses the Airway Inflammation in Asthma

Guidelines for allergy prevention in Hong Kong

Contact Info

Product

Resources

About